Pharming Group NV Total Liabilities
Pharming Group NV total liabilities. Based on the latest financial reports, Pharming Group NV (PHAR) has total liabilities worth $220.41 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Pharming Group NV (PHAR) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Pharming Group NV (2005–2025)
Total liabilities of Pharming Group NV from 2005 to 2025. This chart illustrates how Pharming Group NV's total liabilities have evolved over time, based on quarterly financial data. Explore Pharming Group NV strategic investment ratio to see how much of total assets are deployed in long-term investments.
Pharming Group NV Competitors by Total Liabilities
The table below lists competitors of Pharming Group NV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
First Community Bancshares Inc
NASDAQ:FCBC
|
USA | $3.07 Billion |
|
Jiangsu Zongyi Co Ltd
SHG:600770
|
China | CN¥1.25 Billion |
|
Huadian Power International Corporation Limited
F:SHX
|
Germany | €155.16 Billion |
|
Jiangsu Shentong Valve Co Ltd
SHE:002438
|
China | CN¥2.42 Billion |
|
ZYNP Corp
SHE:002448
|
China | CN¥2.40 Billion |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
|
China | CN¥667.46 Million |
|
Suzhou New District Hi Tech Industrial Co Ltd
SHG:600736
|
China | CN¥59.74 Billion |
|
ASGN Inc
NYSE:ASGN
|
USA | $1.88 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Pharming Group NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see PHAR asset base.
Liquidity & Leverage Metrics
Pharming Group NV Total Liabilities Ratios Explained
Pharming Group NV total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pharming Group NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pharming Group NV (2005–2025)
The table below shows the annual total liabilities of Pharming Group NV from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $222.79 Million | +24.52% |
| 2024-12-31 | $178.92 Million | -26.69% |
| 2023-12-31 | $244.07 Million | +10.36% |
| 2022-12-31 | $221.16 Million | +8.20% |
| 2021-12-31 | $204.40 Million | +6.24% |
| 2020-12-31 | $192.39 Million | +38.88% |
| 2019-12-31 | $138.53 Million | -20.76% |
| 2018-12-31 | $174.81 Million | -1.14% |
| 2017-12-31 | $176.82 Million | +69.29% |
| 2016-12-31 | $104.45 Million | +182.34% |
| 2015-12-31 | $37.00 Million | +17.58% |
| 2014-12-31 | $31.46 Million | -13.68% |
| 2013-12-31 | $36.45 Million | +12.52% |
| 2012-12-31 | $32.40 Million | -3.43% |
| 2011-12-31 | $33.55 Million | -7.23% |
| 2010-12-31 | $36.16 Million | -40.72% |
| 2009-12-31 | $60.99 Million | -19.70% |
| 2008-12-31 | $75.96 Million | -34.60% |
| 2007-12-31 | $116.14 Million | +200.99% |
| 2006-12-31 | $38.59 Million | +457.08% |
| 2005-12-31 | $6.93 Million | -- |
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more